Clinical trial
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast…
NCT00042003 · Astex Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00042003 |
|---|---|
| Title | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) |
| Official title | A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Blast Phase Refractory to Imatinib Mesylate (STI 571) |
| Lead sponsor | Astex Pharmaceuticals, Inc., Industry |
| Collaborators | Eisai Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | decitabine (5-aza-2'deoxycytidine) |
| Enrollment | 40 |
| Start date | Jul 1, 2002 |
| Primary completion | Dec 1, 2004 |
| First posted | Jul 23, 2002 |
| Last update posted | Aug 2, 2024 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: